3JEROME KR, GRETCH DR. Laboratory approaches to the diagnosis of hepatitis C virus infection [J]. Minerva Gastroerterol Dietol, 2004, 50:9-20.
4CHEVALIEZ S, PAWLOTSKY JM. Use of virologic assays in the diagnosis and management of hepatitis C virus infection [J]. Clin Liver Dis, 2005, 9:371-382.
5KUO G, CHOO QL, ALTER HJ, et al. An assay for circulating antibodies to a major etiologic virus of human non-A, non-B hepatitis [J]. Science, 1989, 244;362-364.
6COLIN C, LANOIR D, TOUZET S, et al. Sensitivity and specificity of third-generation hepatitis C virus antibody detection assays: an analysis of the literature [J]. J Viral Hepat, 2001, 8: 87-95.
7NIKOLAEVA LI, BLOKHINA NP, TSURIKOVA NN, et al. Virus specific antibody titres in different phases of hepatitis C virus infection [J]. J Viral Hepat, 2002, 9:429-437.
8BOUVIER\ALIAS M, PATEL K, DAHARI H, et al.Clinical utility of total HCV core antigen quantification: a new indirect marker of HCV replication [J]. Hepatology,2002, 36: 211-218.
9VEILLON P, PAYAN C, PICCHIO G, et al.Comparative evaluation of the total hepatitis C virus core antigen, branched-DNA, and amplicor monitor assays in determining viremia for patients with chronic hepatitis C during interferon plus ribavirin combination therapy [J]. J Clin Microbiol, 2003, 41: 3212-3220.
10BUTI M, MENDEZ C, SCHAPER M, et al. Hepatitis C virus core antigen as a predictor of non-response in genotype 1 chronic hepatitis C patients treated with peginterferon alpha-ab plus ribavirin [J]. J Hepatol,2004, 40: 527-532.
4Camma C, Bruno S, Schepis F, et al. Retreatment with interferon plus ribavirin of chronic hepatitis C non- responders to interferon monotherapy: a meta- analysis of individual patient data[ J ]. Gut, 2002,51:864-869.
5Papatheodoridis GV, Papadimitropoulos VC, Hsdziyannis SJ. Effect of interferon therapy on the development of hepatocellular carcinoma in patients with hepatitis C virus- reated cirrhosis: a meta- analysis[J] .Aliment Pnarmaool Ther, 2001,15:689- 698.
6Kjaergard LL, Krogsgaard K, Gluud C. Interfern alfa with or without ribavirin for chronic hepatitis C: systematic review of randonmised trials[J].BMJ, 2001,323:1151 - 1155.
7Alberti A, Benvegnu L. Management of hepatitis[J] .J Hepatol, 2003,38(Suppl1): S1014 - S1 18.
8Poynard T, MdHutchison J, Davis GL, et al. Impact of interferon alfa - 2b and ribavirin on progression of liver fibrosiis in patients with chronic hepatitis C[J].Hepatology, 2000,32:1131 - 1137.
9Booth JCL, O' Grady J, Neuberger J. Clinical guidelines on the mangement of hepatitis C[J]. Gut, 2001, 49(Suppl I ): il - i12.
10Chander G, Sulkowski MS, Jenckes MW, et al. Treatment of chronic hepatitis C: a systemic review[J]. Hepatology, 2002, 36(5 Suppl 1 ):S135 - S144.
